🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

China Collaborative Study on Epidemiology of Acute Kidney Injury

Recruitingn/aAges any - anyAllXinLing Liang
NCT03054142 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO) Exclusion Criteria: * Serum creatinine record less than two times during hospitalization * Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5) * Nephrectomy * Kidney transplantation * Peak serum creatinine of less than 53µ mol/L * Serum creatinine decrease after amputation
💊

What it tests

  • no intervention
📍

Where

1 site
Nephrology Dept,Guangdong General Hospital
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy